File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children

TitleInfluenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children
Authors
Issue Date2010
PublisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
Citation
Vaccine, 2010, v. 28 n. 6, p. 1566-1574 How to Cite?
AbstractChildren aged 11 to <24 months received 2 intranasal doses of live attenuated influenza vaccine (LAIV) or placebo, 35 ± 7 days apart. Dose 1 was administered concomitantly with a combined measles, mumps, and rubella vaccine (Priorix). Seroresponses to measles and mumps were similar between groups. Compared with placebo, response rates to rubella in LAIV + Priorix recipients were statistically lower at a 15 IU/mL threshold (83.9% vs 78.0%) and the prespecified noninferiority criteria were not met. In a post hoc analysis using an alternate widely accepted threshold of 10 IU/mL, the noninferiority criteria were met (93.4% vs 89.8%). Concomitant administration with Priorix did not affect the overall influenza protection rate of LAIV (78.4% and 63.8% against antigenically similar influenza strains and any strain, respectively). © 2009 Elsevier Ltd. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/170432
ISSN
2015 Impact Factor: 3.413
2015 SCImago Journal Rankings: 2.044
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLum, LCSen_US
dc.contributor.authorBorjaTabora, CFen_US
dc.contributor.authorBreiman, RFen_US
dc.contributor.authorVesikari, Ten_US
dc.contributor.authorSablan, BPen_US
dc.contributor.authorChay, OMen_US
dc.contributor.authorTantracheewathorn, Ten_US
dc.contributor.authorSchmitt, HJen_US
dc.contributor.authorLau, YLen_US
dc.contributor.authorBowonkiratikachorn, Pen_US
dc.contributor.authorTam, JSen_US
dc.contributor.authorLee, BWen_US
dc.contributor.authorTan, KKen_US
dc.contributor.authorPejcz, Jen_US
dc.contributor.authorCha, Sen_US
dc.contributor.authorGutierrezBrito, Men_US
dc.contributor.authorKaltenis, Pen_US
dc.contributor.authorVertruyen, Aen_US
dc.contributor.authorCzajka, Hen_US
dc.contributor.authorBojarskas, Jen_US
dc.contributor.authorBrooks, WAen_US
dc.contributor.authorCheng, SMen_US
dc.contributor.authorRappaport, Ren_US
dc.contributor.authorBaker, Sen_US
dc.contributor.authorGruber, WCen_US
dc.contributor.authorForrest, BDen_US
dc.date.accessioned2012-10-30T06:08:30Z-
dc.date.available2012-10-30T06:08:30Z-
dc.date.issued2010en_US
dc.identifier.citationVaccine, 2010, v. 28 n. 6, p. 1566-1574en_US
dc.identifier.issn0264-410Xen_US
dc.identifier.urihttp://hdl.handle.net/10722/170432-
dc.description.abstractChildren aged 11 to <24 months received 2 intranasal doses of live attenuated influenza vaccine (LAIV) or placebo, 35 ± 7 days apart. Dose 1 was administered concomitantly with a combined measles, mumps, and rubella vaccine (Priorix). Seroresponses to measles and mumps were similar between groups. Compared with placebo, response rates to rubella in LAIV + Priorix recipients were statistically lower at a 15 IU/mL threshold (83.9% vs 78.0%) and the prespecified noninferiority criteria were not met. In a post hoc analysis using an alternate widely accepted threshold of 10 IU/mL, the noninferiority criteria were met (93.4% vs 89.8%). Concomitant administration with Priorix did not affect the overall influenza protection rate of LAIV (78.4% and 63.8% against antigenically similar influenza strains and any strain, respectively). © 2009 Elsevier Ltd. All rights reserved.en_US
dc.languageengen_US
dc.publisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccineen_US
dc.relation.ispartofVaccineen_US
dc.subject.meshAdministration, Intranasalen_US
dc.subject.meshAntibodies, Viral - Blooden_US
dc.subject.meshDrug Incompatibilityen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshInfanten_US
dc.subject.meshInfluenza Vaccines - Administration & Dosage - Immunologyen_US
dc.subject.meshInfluenza, Human - Prevention & Controlen_US
dc.subject.meshMaleen_US
dc.subject.meshMeasles - Prevention & Controlen_US
dc.subject.meshMeasles-Mumps-Rubella Vaccine - Administration & Dosage - Immunologyen_US
dc.subject.meshMumps - Prevention & Controlen_US
dc.subject.meshPlacebos - Administration & Dosageen_US
dc.subject.meshRubella - Prevention & Controlen_US
dc.subject.meshVaccination - Methodsen_US
dc.subject.meshVaccines, Attenuated - Administration & Dosage - Immunologyen_US
dc.subject.meshVaccines, Combined - Administration & Dosage - Immunologyen_US
dc.titleInfluenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young childrenen_US
dc.typeArticleen_US
dc.identifier.emailLau, YL:lauylung@hkucc.hku.hken_US
dc.identifier.authorityLau, YL=rp00361en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/j.vaccine.2009.11.054en_US
dc.identifier.pmid20003918-
dc.identifier.scopuseid_2-s2.0-75449104808en_US
dc.identifier.hkuros170383-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-75449104808&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume28en_US
dc.identifier.issue6en_US
dc.identifier.spage1566en_US
dc.identifier.epage1574en_US
dc.identifier.isiWOS:000275301900021-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridLum, LCS=7006122536en_US
dc.identifier.scopusauthoridBorjaTabora, CF=6506767279en_US
dc.identifier.scopusauthoridBreiman, RF=34567511600en_US
dc.identifier.scopusauthoridVesikari, T=7006054851en_US
dc.identifier.scopusauthoridSablan, BP=6505467962en_US
dc.identifier.scopusauthoridChay, OM=6701788148en_US
dc.identifier.scopusauthoridTantracheewathorn, T=6506913050en_US
dc.identifier.scopusauthoridSchmitt, HJ=7402688911en_US
dc.identifier.scopusauthoridLau, YL=7201403380en_US
dc.identifier.scopusauthoridBowonkiratikachorn, P=6507156486en_US
dc.identifier.scopusauthoridTam, JS=24788939600en_US
dc.identifier.scopusauthoridLee, BW=7405437980en_US
dc.identifier.scopusauthoridTan, KK=24448887300en_US
dc.identifier.scopusauthoridPejcz, J=6603213807en_US
dc.identifier.scopusauthoridCha, S=8710958100en_US
dc.identifier.scopusauthoridGutierrezBrito, M=16244906200en_US
dc.identifier.scopusauthoridKaltenis, P=6603285434en_US
dc.identifier.scopusauthoridVertruyen, A=6504327374en_US
dc.identifier.scopusauthoridCzajka, H=6507061121en_US
dc.identifier.scopusauthoridBojarskas, J=6506667432en_US
dc.identifier.scopusauthoridBrooks, WA=35338978000en_US
dc.identifier.scopusauthoridCheng, SM=36016290000en_US
dc.identifier.scopusauthoridRappaport, R=7102851109en_US
dc.identifier.scopusauthoridBaker, S=8323764300en_US
dc.identifier.scopusauthoridGruber, WC=7101809290en_US
dc.identifier.scopusauthoridForrest, BD=7005933383en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats